Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Avadel Pharmaceuticals ( (AVDL) ).
On June 22, 2023, Jazz Pharmaceuticals filed a lawsuit against the FDA and other entities, challenging the approval of Avadel Pharmaceuticals‘ drug LUMRYZ. The lawsuit claimed the approval was unlawful. On October 30, 2024, the D.C. Court ruled in favor of the FDA and Avadel, rejecting Jazz’s claims. Jazz appealed the decision, but on June 27, 2025, the D.C. Court of Appeals upheld the original ruling, affirming the FDA’s approval of LUMRYZ.
The most recent analyst rating on (AVDL) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.
Spark’s Take on AVDL Stock
According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.
Avadel Pharmaceuticals’ overall stock score is bolstered by strong earnings call outcomes and positive corporate events, which signal growth opportunities and strategic advancements. However, financial performance issues and valuation concerns moderate the score.
To see Spark’s full report on AVDL stock, click here.
More about Avadel Pharmaceuticals
Average Trading Volume: 1,349,853
Technical Sentiment Signal: Sell
Current Market Cap: $914.7M
For detailed information about AVDL stock, go to TipRanks’ Stock Analysis page.